# Larimar Therapeutics Q3 2026 Results

> Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.
- Title: Larimar Therapeutics Q3 2026 Results | Shortify
- Summary: Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc.
- Keywords: earnings, inc., larimar therapeutics, lrmr, q3 2026, net loss, cell-penetrating peptide, rare disease treatments, Alphastreet - Earnings Decoded. Market Intelligence Delivered
- URL: https://shortify.news/story/larimar-therapeutics-q3-2026-results
- Source: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/larimar-therapeutics-releases-q3-2026-financial-results
- Author: AlphaStreet Newsdesk
- Published: 2026-11-16T14:46:55+00:00
- Read time: 1 min
- Topics: earnings, inc., larimar therapeutics, lrmr, q3 2026, net loss, cell-penetrating peptide, rare disease treatments
## Q3 2026 Financial Results
Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026.
## Per-Share Loss Narrowed
The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.
## Analyst Support
Wall Street maintains a broadly positive view with 8 buy, 1 hold, 0 sell consensus.
## Key takeaway

Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025.

---

Summary: Shortify — https://shortify.news/story/larimar-therapeutics-q3-2026-results
Reporting: Alphastreet - Earnings Decoded. Market Intelligence Delivered — https://news.alphastreet.com/larimar-therapeutics-releases-q3-2026-financial-results

When you use this summary, link the Shortify URL for the summary and credit the reporting to its newsroom.